Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Stake Lessened by Jane Street Group LLC

Jane Street Group LLC trimmed its stake in shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Free Report) by 89.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,071 shares of the company's stock after selling 106,732 shares during the quarter. Jane Street Group LLC's holdings in Aveanna Healthcare were worth $55,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. First Eagle Investment Management LLC acquired a new stake in shares of Aveanna Healthcare in the 4th quarter valued at about $1,992,000. Swiss National Bank bought a new stake in Aveanna Healthcare in the fourth quarter valued at about $434,000. Federated Hermes Inc. raised its stake in Aveanna Healthcare by 3,047.2% during the fourth quarter. Federated Hermes Inc. now owns 89,665 shares of the company's stock valued at $410,000 after buying an additional 86,816 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Aveanna Healthcare by 80.5% during the 4th quarter. JPMorgan Chase & Co. now owns 154,703 shares of the company's stock worth $707,000 after buying an additional 68,989 shares during the last quarter. Finally, Tudor Investment Corp ET AL grew its position in shares of Aveanna Healthcare by 30.7% in the 4th quarter. Tudor Investment Corp ET AL now owns 214,978 shares of the company's stock worth $982,000 after acquiring an additional 50,514 shares in the last quarter. 87.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Aveanna Healthcare

In related news, major shareholder Paul R. Vigano sold 1,560,700 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.36, for a total value of $8,365,352.00. Following the sale, the insider now owns 29,640,756 shares of the company's stock, valued at $158,874,452.16. This trade represents a 5.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder J.H. Whitney Equity Partners V sold 47,039 shares of the business's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $5.72, for a total transaction of $269,063.08. Following the transaction, the insider now directly owns 1,447,191 shares of the company's stock, valued at $8,277,932.52. The trade was a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,887,612 shares of company stock worth $26,269,057. 7.80% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AVAH shares. Truist Financial dropped their price target on Aveanna Healthcare from $6.00 to $5.50 and set a "hold" rating on the stock in a research report on Friday, April 11th. UBS Group increased their target price on shares of Aveanna Healthcare from $4.50 to $5.00 and gave the stock a "sell" rating in a report on Friday, May 9th.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH opened at $5.51 on Monday. The stock has a 50 day moving average of $5.08 and a 200-day moving average of $4.92. The firm has a market capitalization of $1.07 billion, a PE ratio of -16.21 and a beta of 2.03. Aveanna Healthcare Holdings Inc. has a 52 week low of $2.32 and a 52 week high of $6.19.

Aveanna Healthcare Company Profile

Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.